This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Peramivir oral

BioCryst Pharmaceuticals, Inc.

Drug Names(s): RWJ-270201, BCX-1812

Description: Peramivir oral is an influenza neuraminidase inhibitor that, in preclinical studies, has shown potent, broad-spectrum activity against multiple strains of flu, including the H5N1 virus.

Neuraminidase is an enzyme essential for the influenza virus to replicate and infect its hosts. The enzyme neuraminidase is responsible for the release of particles from infected cells. These particles then spread the disease and may also assist in spreading the virus through the mucus allowing it to escape the host through a sneeze or a cough, and infect others.

Deal Structure: In September 1998, BioCryst entered an exclusive worldwide license agreement with The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil to develop and market proprietary influenza neuraminidase inhibitors.

In April 2001, BioCryst announced Ortho-McNeilPharmaceuticals and the R.W. Johnson Pharmaceutical Research Institute, gave fourmonths prior notice of termination of the worldwide license agreement with BioCryst to develop and market products to treat and prevent viral influenza. Ortho-McNeil indicatedthat this business decision was not related to safety or efficacy of the drug, but that other of its drug development programs were of a higher priority.

Termination by Ortho-McNeil returned all rights to BioCryst's proprietary influenza neuraminidase inhibitors back to BioCryst. In addition, Ortho-McNeil was to transfer to BioCryst any and all improvements, information, data and materials connected to the licensed product including, but not limited to, clinical and...See full deal structure in Biomedtracker

Peramivir oral News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug